Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

Notice Regarding Change in Responsibilities of a Director

TOKYO, November 4, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi) hereby announces that it has decided, effective November 4, 2026, to change the responsibilities of a Director as described below.

1. Reason for the Change

To promote the human capital strategy of the ASKA Pharmaceutical Holdings Group, the Company has appointed a Director to be in charge of Human Capital Strategy.

2. Change in Responsibilities of a Director

Maiko Mori	**[New Responsibilities]** Member of the Board of Directors, Executive Corporate Officer, In charge of Human Capital Strategy of the Company **[Current Responsibilities]** Member of the Board of Directors, Executive Corporate Officer

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Group Management Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

Reference (As of November 4, 2026)

1. Board Members (excluding Board Members who are Audit & Supervisory Committee Members)

Takashi Yamaguchi	Member of the Board of Directors, Representative Director, Chairman of the Board (Member of the Board of Directors, Representative Director, Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Sohta Yamaguchi	President, Member of the Board of Directors, Representative Director (President, Member of the Board of Directors, Representative Director of ASKA Pharmaceutical Co., Ltd.)
Atsushi Maruo	Senior Managing Member of the Board of Directors, Representative Director, In Charge of Sustainability (Member of the Board of Directors, Vice Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Maiko Mori	Member of the Board of Directors, Executive Corporate Officer, In charge of Human Capital Strategy of the Company (Member of the Board of Directors, Executive Corporate Officer, Quality & Safety Assurance Division Director of ASKA Pharmaceutical Co., Ltd.)
Fumiyoshi Yamaguchi	Member of the Board of Directors, Executive Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Animal Health Co., Ltd.)
Minoru Awabayashi	Member of the Board of Directors, Outside Director
Yasuji Enokido	Member of the Board of Directors, Outside Director
Kanae Karita	Member of the Board of Directors, Outside Director
Kiyoko Kato	Member of the Board of Directors, Outside Director
James C. Feliciano	Member of the Board of Directors, Outside Director

2. Board Members who are Audit & Supervisory Committee Members

Kunihiro Gunji	Member of the Board of Directors, Audit and Supervisory Committee Member (Audit & Supervisory Board Member of ASKA Pharmaceutical Co., Ltd., Audit & Supervisory Board Member of ASKA Pharma Medical Co., Ltd.)
Takao Kimura	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member
Koki Yamashita	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member

3. Corporate Officers

Kiyohiko Tamura	Executive Corporate Officer, Group Business Management Division Director In Charge of DX Promotion Group Legal Affairs Department Director (Executive Corporate Officer, Administrative Division Director of ASKA Pharmaceutical Co., Ltd.)
Tomohito Nagao	Corporate Officer, In Charge of Group Audit and Group Compliance, Group Compliance Office Director (Corporate Officer, Promotion Compliance Unit Director of ASKA Pharmaceutical Co., Ltd.)
Hidenori Hori	Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Pharma Medical Co., Ltd.)